|
T12928 |
SK33
|
|
Androgen Receptor
|
|
SK33 is a potent and tissue selective anti-androgen agent. SK33 reduces androgen receptor (AR) transcriptional activity. |
|
T1267 |
Abacavir
|
Epzicom,Ziagen,Abacavir sulfate |
Apoptosis
,
HIV Protease
,
Reverse Transcriptase
|
|
Abacavir (Ziagen) is a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS. |
|
T1448 |
Dasatinib
|
BMS-354825 |
Apoptosis
,
Bcr-Abl
,
Src
,
c-Kit
,
Autophagy
|
|
Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitumor activity and is used in the treatment of leukemia and ly... |
|
T6967 |
RHPS4
|
RHPS 4 methosulfate,NSC714187 |
Apoptosis
,
Telomerase
|
|
RHPS4 (RHPS 4 methosulfate) is a potent inhibitor of Telomerase at submicromolar. |
|
T6367 |
Abacavir sulfate
|
Abacavir Hemisulfate,1592U89,ABC sulfate,Ziagen |
Apoptosis
,
HIV Protease
,
Reverse Transcriptase
|
|
Abacavir sulfate (Ziagen) , a nucleoside analogue, effectively utilize its antiviral activity |
|
T1448L |
Dasatinib monohydrate
|
BMS-354825 Monohydrate |
Apoptosis
,
Bcr-Abl
,
Src
,
c-Kit
,
Ephrin Receptor
,
Autophagy
|
|
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activit... |
|
T79054 |
TRPC3/6-IN-2
|
|
|
|
TRPC3/6-IN-2 is a potent inhibitor of TRPC3 and TRPC6, exhibiting IC50 values of 16 nM for TRPC3 and 29.8 nM for TRPC6, respectively [1]. |
|
T29113 |
VPC32183
|
VPC-32183,VPC 32183 |
|
|
VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. |
|
T61407 |
TRPC3/6-IN-1
|
|
|
|
TRPC3/6-IN-1 is a highly potent and selective inhibitor that specifically blocks the activity of the canonical transient receptor channels TRPC3 and TRPC6. It exhibits a significant blocking potency against the human iso... |
|
T35071 |
VPC32179
|
VPC 32179,VPC-32179 |
|
|
VPC32179 is a bioactive chemical. |
|
T10657 |
C75
|
C-75 |
Fatty Acid Synthase
|
|
C75 is an inhibitor synthetic fatty-acid synthase (FASN) and inhibits prostate cancer cells PC3 (IC50: 35 μM). |
|
T35666 |
PRGL493
|
|
Others
|
|
PRGL493 is an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4).1It inhibits formation of arachidonoyl-CoA (AA-CoA) from arachidonic acid in, as well as the proliferation and migration of, PC3 and MDA-MB-231 cancer c... |
|
TP1895L1 |
KYL acetate(676657-00-4 free base)
|
|
Ephrin Receptor
|
|
KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP... |
|
T29110 |
VPC-13163
|
2,3-dihydro-2,3'-Bi-1H-indole,VPC13163,NSC52361,NSC 52361,VPC 13163 |
Others
|
|
VPC-13163 (NSC-52361) has strong anti-proliferative activity against LNCaP and Enzalutamide-resistant prostate cancer cell lines (MR49F) whereas it did not affect the growth of AR independent PC3 cell line. It also inhib... |
|
T3989 |
SMI-16a
|
PIM1/2 Kinase Inhibitor VI |
Pim
|
|
SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (IC50: 150/20 nM) while exhibiting little or no activity against... |
|
T10656 |
Trans-C75
|
(±)-C75 |
Others
,
Fatty Acid Synthase
|
|
trans-C75 ((±)-C75) is an enantiomer of C75. C75 is an inhibitor of fatty-acid synthase (FASN). |
|
T64222 |
Antitumor agent-55
|
|
|
|
Antitumor agent-55 (compound 5q) is a potent antitumour agent that effectively inhibits PC3 (IC50: 0.91 μM). antitumor agent-55 blocks the G1/S phase of the PC3 cell cycle, induces apoptosis, inhibits cell migration and ... |
|
T36991 |
Monascuspiloin
|
|
|
|
Monascuspiloin is a fungal metabolite that has been found inM. pilosusM93-fermented rice.1It induces endoplasmic reticulum stress and autophagy in PC3 prostate cancer cells. Monascuspiloin (15-45 μM) decreases viability ... |
|
T72468 |
Anticancer agent 25
|
|
|
|
Anticancer agent 25 demonstrates the highest level of cytotoxic effectiveness on PC3 cells, achieving an IC 50 value of 0.19 μM. |
|
T68441 |
SABRAC
|
|
|
|
SABRAC inhibits acid ceramidase in PC3 MC metastatic prostate cancer cells (IC50 = <1 µM), as well as induces accumulation of ceramides in the same cells. |
|
T78051 |
Necrocide 1
|
|
Others
|
|
Necrocide 1 (compound (S)-38), a potent anticancer agent, exhibits antiproliferative activity with IC50 values of 0.48 nM for MCF-7 and 2 nM for PC3 cancer cell lines, respectively [1]. |
|
T10924 |
Cysteine protease inhibitor-2
|
|
Cysteine Protease
|
|
Cysteine protease inhibitor 2 is a cysteine protease inhibitor. Cysteine protease inhibitor 2 inhibited DCT116 and PC3 cells with GI50 values of 6.5 μM and 4.4 μM, respectively. |
|
T35855 |
AAA
|
|
|
|
AAA is an antagonist of G protein-coupled receptor 75 (GPR75).1It increases basal GPR75 protein levels and inhibits 20-HETE-induced reductions in GPR75 protein levels in PC3 cells. AAA (5 and 10 μM) also reduces 20-HETE-... |
|
T74299 |
MS5033
|
|
|
|
MS5033 is a potent proteolysis-targeting chimera (PROTAC) that effectively degrades AKT (also known as protein kinase B), exhibiting a half-maximal degradation concentration (DC50) of 430 nM in PC3 cells [1]. |
|
T36628 |
PROTAC BRD4 Degrader-8
|
PROTAC BRD4 Degrader-8 |
|
|
PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells... |
|
T83007 |
Antitumor agent-120
|
|
|
|
Antitumor agent-120 (compound 1), a flavonoid derived from Kudzu root, exhibits negligible inhibitory effects on LNCaP and PC3 cancer cells, with IC50 values exceeding 50 μM [1]. |
|
T70962 |
MHY219
|
|
|
|
MHY219 is a novel HDAC inhibitor. MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. MHY219 was shown to enhance the cytotoxicity on DU145 cells (IC50, 0.36 μM) whe... |
|
T61902 |
Anticancer agent 69
|
|
|
|
Anticancer agent 69 (Compound 34) is an effective selective anticancer agent with selective inhibition on human prostate cancer cell line PC3 (IC50=26 nM). Anticancer agent 69 can increase ROS level and down-regulate EGF... |
|
T35940 |
Darinaparsin
|
Dimethylarsinic glutathione,Darinaparsin |
|
|
Darinaparsin is a dimethylated arsenic linked to glutathione. It is cytotoxic to DU145, LNCaP, and PC3 prostate cancer cells (IC50s = 5-10 µM) and patient-derived primary prostate cancer cells (IC50s = 2.5-20 µM)... |
|
T74126 |
PROTAC BRD4 Degrader-14
|
|
|
|
PROTAC BRD4 Degrader-14, a PROTAC (Proteolysis Targeting Chimera) linked by ligands to von Hippel-Lindau and BRD4, exhibits IC50 values of 1.8 nM and 1.7 nM for BRD4 BD1 and BD2, respectively. This compound effectively d... |
|
T74300 |
MS143
|
|
|
|
MS143, a potent AKT degrader (DC50=46 nM and GI50=0.8 µM in PC3 cells), effectively induces AKT degradation through the ubiquitin-proteasome system in both a concentration- and time-dependent manner, leading to the suppr... |
|
T35629 |
ATRA-BA Hybrid
|
|
|
|
ATRA-BA hybrid is a mutual prodrug form of all-transretinoic acid and butyric acid .1ATRA-BA hybrid is cleaved to release ATRA and BA in isolated mouse plasma. It inhibits the growth of MDA-MB-231 breast and PC3 prostate... |
|
T79202 |
Anticancer agent 118
|
|
|
|
Anticancer Agent 118, an N‑acylated ciprofloxacin derivative, exhibits antibacterial efficacy against Gram-positive strains and antiproliferative effects on prostate PC3 cells, making it a potential candidate for antitum... |
|
T74125 |
PROTAC BRD4 Degrader-12
|
|
|
|
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC that links von Hippel-Lindau and BRD4 ligands. When conjugated with STEAP1 and CLL1 antibodies, this compound effectively degrades BRD4 protein in PC3 prostate cancer cel... |
|
T70792 |
SPR519
|
|
|
|
SPR519 is a potent dual inhibitor of PI3Kα and mTOR kinases with IC50 (PI3Kalpha) = 30 nM and IC50 (mTOR) = 10 nM. SPR519 exhibits an EC50 of low sub-micromolar range among various tested cancer cell lines such as A2780... |
|
T40072 |
PROTAC BRD4 Degrader-9
|
PROTAC BRD4 Degrader-9 |
|
|
PROTAC BRD4 Degrader-9 (compound 8a) is a novel chemical compound consisting of ligands for von Hippel-Lindau and BRD4, connected by a PROTAC moiety. This compound can effectively degrade the BRD4 protein in PC3 prostate... |
|
T78980 |
Pim-1 kinase inhibitor 5
|
|
Pim
|
|
Pim-1 kinase inhibitor 5 (Compound 4c), with an IC50 of 0.61 μM, exhibits cytotoxicity against various cancer cell lines, including HepG2, MCF-7, PC3, and HCT-116, with IC50 values ranging from 6.95 to 20.19 μM [1]. |
|
T82089 |
ICMT-IN-53
|
|
|
|
ICMT-IN-53 (compound 12) is an ICMT inhibitor exhibiting an IC50 of 0.96 μM, alongside favorable PAMPA permeability and antiproliferative properties. It demonstrates efficacy by inhibiting the proliferation of MDA-MB-231... |
|
T35561 |
MS351
|
|
|
|
MS351 is an antagonist of chromobox 7 (CBX7) that acts by binding the CBX7 chromodomain. It enhances the binding of long noncoding RNA to the CBX7 chromodomain when used at 25 μM. MS351 induces transcriptional derepressi... |
|
T40073 |
PROTAC BRD4 Degrader-10
|
PROTAC BRD4 Degrader-10 |
|
|
PROTAC BRD4 Degrader-10, also known as compound 8b, is a dual ligand-based PROTAC that combines ligands for von Hippel-Lindau and BRD4. To degrade the BRD4 protein in PC3 prostate cancer cells, PROTAC BRD4 Degrader-10 ca... |
|
T40074 |
PROTAC BRD4 Degrader-15
|
PROTAC BRD4 Degrader-15 |
|
|
PROTAC BRD4 Degrader-15 is a chemical compound consisting of a PROteolysis TArgeting Chimera (PROTAC) linked to ligands specific to von Hippel-Lindau and BRD4. It exhibits an IC50 of 7.2 nM for BRD4 BD1 and 8.1 nM for BR... |
|
T74124 |
PROTAC BRD4 Degrader-11
|
|
|
|
PROTAC BRD4 Degrader-11 (compound 9a), a PROTAC linked through ligands to von Hippel-Lindau and BRD4, effectively targets and degrades the BRD4 protein in PC3 prostate cancer cells when conjugated with STEAP1 and CLL1 an... |
|
TP1895 |
KYL peptide
|
KYL |
|
|
KYL peptide is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP... |
|
T62278 |
Anticancer agent 36
|
|
|
|
Anticancer agent 36 (compound 11) is a potent anti-microbial and anti-cancer agent, a sulfonylurea derivative. anticancer agent 36 inhibits the microbial growth of Bacillus mycoides, Escherichia coli and Candida albicans... |
|
T62754 |
Anticancer agent 34
|
|
|
|
Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida al... |
|
T63947 |
GRPR antagonist-1
|
|
|
|
GRPR antagonist-1 is a potent antagonist of the gastrin-releasing peptide receptor (GRPR) and is cytotoxic to certain cancer cells (able to act on PC3 cells (IC50: 4.97 μM), Pan02 cells (IC50: 4.36 μM), HGC-27 cells (IC5... |
|
T40075 |
PROTAC BRD4 Degrader-13
|
PROTAC BRD4 Degrader-13 |
|
|
PROTAC BRD4 Degrader-13 (compound 9d) is a bioactive compound that functions as a proteolysis targeting chimera (PROTAC), linking ligands for von Hippel-Lindau and BRD4 proteins. In the context of PC3 prostate cancer cel... |
|
T73125 |
SMTIN-T140
|
|
HSP
|
|
SMTIN-T140 (compound 6a), a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor with an IC50 of 1.646 μM, exhibits anticancer activity by inducing mitochondrial dysfunction, elevating mitochondri... |
|
T15205 |
EL-102
|
EL102 |
Microtubule Associated
,
HIF
|
|
EL-102 is a HIF1α inhibitor with anticancer activity that inhibits microtubule protein polymerization and can be used to study prostate cancer. |
|
T79557 |
Fac-[Re(CO)3(L6)(H2O)][NO3]
|
|
Apoptosis
|
|
Compound 6, fac-[Re(CO)3(L6)(H2O)][NO3], a rhenium(I) tricarbonyl aqua complex, serves as an anticancer agent by disrupting mitochondrial function. It exhibits cytotoxicity against prostate cancer cells with an IC50 of 5... |
